Skip to main content

Table 1 Registered clinical studies regarding the application of MSCs in patients with ARDS

From: Genetically modified mesenchymal stem cell therapy for acute respiratory distress syndrome

ClinicalTrials.gov identifier

Study title

Study phase

Actual/estimated enrollment

Cell source

Cell does

Primary outcome

Location

Status

NCT01775774

Human mesenchymal stem cells for acute respiratory distress syndrome (START)

Phase 1

9 participants

Bone marrow MSCs

1 × 106,5 × 106, and 10 × 106 cells/kg

Infusion associated adverse events

USA

Completed

NCT03608592

Human umbilical cord-derived mesenchymal stem cells therapy in acute respiratory distress syndrome

Phase 1

12 participants

Umbilical cord-derived MSCs

1 × 106 cells

Infusion associated events

China

Not yet recruiting

NCT02804945

Mesenchymal stem cells (MSCs) for treatment of acute respiratory distress syndrome (ARDS) in patients with malignancies

Phase 1

20 participants

Bone marrow MSCs

3 × 106/cells/kg

Adverse events

USA

Active, not recruiting

NCT01902082

Adipose-derived mesenchymal stem cells in acute respiratory distress syndrome

Phase 1

20 participants

Adipose-derived MSCs

1 × 106/cells/kg

Adverse events

China

Completed

NCT02444455

Human umbilical-cord-derived mesenchymal stem cell therapy in acute lung injury (UCMSC-ALI)

Phase 1/2

20 participants

Human umbilical cord MSCs

5 × 105/cells/kg

Major adverse events

China

Recruiting

NCT02112500

Mesenchymal stem cell in patients with acute severe respiratory failure (STELLAR)

Phase 2

10 participants

Bone marrow MSCs

Unclear

Oxygen index at 3 days after MSCs infusion

Korea

Unknown

NCT03042143

Repair of acute respiratory distress syndrome by stromal cell administration (REALIST)

Phase 1/2

75 participants

Umbilical cord-derived MSCs

Unclear

Oxygenation index, serious adverse events

UK

Recruiting